2024
Uveitis Onset and Flare-Up: Does the Time of Year Matter?
Surapaneni L, Orlofsky P, Kombo N. Uveitis Onset and Flare-Up: Does the Time of Year Matter? Ocular Immunology And Inflammation 2024, 32: 2299-2305. PMID: 38411923, DOI: 10.1080/09273948.2024.2320701.Peer-Reviewed Original ResearchConceptsComorbid autoimmune conditionsUveitis episodeAutoimmune conditionsPosterior uveitisFlare-upHLA-B27Cases of endogenous uveitisHLA-B27 positive patientsIncidence of flare-upsAnatomic location of uveitisDiagnosis of uveitisLocation of uveitisRetrospective chart reviewNon-infectiousTime of onsetIntermediate uveitisUveitis patientsChronic uveitisAnterior uveitisCommunity-based clinicsEndogenous uveitisUveitis onsetPatient agePositive patientsPanuveitis casesOral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study
Garcia-Manero G, McCloskey J, Griffiths E, Yee K, Zeidan A, Al-Kali A, Deeg H, Patel P, Sabloff M, Keating M, Zhu N, Gabrail N, Fazal S, Maly J, Odenike O, Kantarjian H, DeZern A, O'Connell C, Roboz G, Busque L, Buckstein R, Amin H, Randhawa J, Leber B, Shastri A, Dao K, Oganesian A, Hao Y, Keer H, Azab M, Savona M. Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. The Lancet Haematology 2024, 11: e15-e26. PMID: 38135371, DOI: 10.1016/s2352-3026(23)00338-1.Peer-Reviewed Original ResearchConceptsChronic myelomonocytic leukemiaIntravenous decitabineMyelodysplastic syndromeMyelomonocytic leukemiaOral therapyPrimary endpointAdverse eventsEastern Cooperative Oncology Group performance status 0Treatment cyclesCycle 1Full treatment dosePerformance status 0Treatment-related deathsFrequent adverse eventsSerious adverse eventsPhase 3 studyPhase 3 trialPotential treatment benefitsCommunity-based clinicsAcute myeloid leukemiaNext treatment cycleTreatment of individualsOral decitabineStatus 0Treatment discontinuation
2022
Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP)
Cespedes M, Das M, Hojilla JC, Blumenthal J, Mounzer K, Ramgopal M, Hodge T, Torres TS, Peterson C, Shibase S, Elliott A, Demidont AC, Callaghan L, Watson CC, Carter C, Kintu A, Baeten JM, Ogbuagu O. Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP). PLOS ONE 2022, 17: e0267780. PMID: 35657826, PMCID: PMC9165827, DOI: 10.1371/journal.pone.0267780.Peer-Reviewed Original ResearchConceptsClinical trialsHIV incidencePre-exposure prophylaxis clinical trialHispanic/LatinxRecruitment goalsGood participatory practice guidelinesOngoing phase 3 trialsHIV pre-exposure prophylaxisTransgender womenTransgender menPhase 3 trialPre-exposure prophylaxisCommunity-based clinicsFuture clinical trialsClinical trial numberEvidence-informed recommendationsLatinx MSMGender nonbinary individualsCisgender MSMNovel agentsPractice guidelinesStudy populationBlack MSMUS sitesTrials
2018
Survival among Veterans Obtaining Dialysis in VA and Non-VA Settings
Wang V, Coffman CJ, Stechuchak KM, Berkowitz TSZ, Hebert PL, Edelman D, O'Hare AM, Crowley ST, Weidenbacher HJ, Maciejewski ML. Survival among Veterans Obtaining Dialysis in VA and Non-VA Settings. Journal Of The American Society Of Nephrology 2018, 30: 159-168. PMID: 30530657, PMCID: PMC6317601, DOI: 10.1681/asn.2018050521.Peer-Reviewed Original ResearchConceptsCommunity-based clinicsDialysis settingCox proportional hazards modelOutcomes of veteransNon-VA settingsProportional hazards modelProvision of dialysisCause mortalityChronic dialysisClinical characteristicsDialysis initiationDialysis patientsImproved survivalHazards modelMortality rateCare programVeterans AffairsVeteran carePatientsDialysisMortalityMedicareVeteransSurvivalClinic
2008
The Vote and Vax Program
Shenson D, Adams M. The Vote and Vax Program. Journal Of Public Health Management And Practice 2008, 14: 476-480. PMID: 18708892, DOI: 10.1097/01.phh.0000333883.52893.c8.Peer-Reviewed Original ResearchConceptsInfluenza vaccinationAdult vaccine recipientsInfluenza-associated illnessAnnual influenza vaccinationInfluenza vaccination seasonCommunity-based clinicsHalf of adultsPublic health agenciesVaccination recipientsVaccine recipientsVaccination seasonRobert Wood Johnson FoundationVaccinationDisease preventionHealth agenciesMajor causePriority groupsOlder AmericansClinicJohnson FoundationLarge-scale deliveryRecipientsDeliveryPercentHospitalization
1998
Self-reported Antiretroviral Therapy in Injection Drug Users
Celentano D, Vlahov D, Cohn S, Shadle V, Obasanjo O, Moore R. Self-reported Antiretroviral Therapy in Injection Drug Users. JAMA 1998, 280: 544-546. PMID: 9707145, DOI: 10.1001/jama.280.6.544.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusInjection drug usersSelf-reported ART useAntiretroviral therapyART useDrug usersCombination therapyProtease inhibitorsRecent human immunodeficiency virusSelf-reported antiretroviral therapyInternational AIDS Society-USACurrent drug injectorsRecent antiretroviral therapyProtease inhibitor useHalf of patientsUS Public Health ServiceTriple combination therapyCommunity-based clinicsProportion of subjectsHealth care providersCurrent drug useActive drug usersCross-sectional surveyPublic health servicesInhibitor use
1992
Changes in T-Lymphocyte Subsets in Intravenous Drug Users With HIV-1 Infection
Margolick J, Muñoz A, Vlahov D, Solomon L, Astemborski J, Cohn S, Nelson K. Changes in T-Lymphocyte Subsets in Intravenous Drug Users With HIV-1 Infection. JAMA 1992, 267: 1631-1636. PMID: 1347321, DOI: 10.1001/jama.1992.03480120069035.Peer-Reviewed Original ResearchConceptsSeropositive intravenous drug usersIntravenous drug usersHIV-1 infectionHIV-1-seropositive intravenous drug usersDrug usersCell countSeronegative intravenous drug usersHuman immunodeficiency virus type 1Complete blood cell countImmunodeficiency virus type 1Absolute numberCD4 cell countCD4 lymphocyte countPercentage of CD4T lymphocyte subsetsCD8 T cellsT cell subsetsCommunity-based clinicsBlood cell countTime of seroconversionVirus type 1Multivariate regression analysisUse of drugsCD4 lymphocytesCD8 lymphocytes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply